Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis

References

• Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90(9):790–795. doi:10.1002/ajh.24086
   PubMed Web of Science ®Google Scholar
• Smith A, Crouch S, Howell D, Burton C, Patmore R, Roman E. Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol. 2015;39(6):1103–1112. doi:10.1016/j.canep.2015.08.015
   PubMed Web of Science ®Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459. doi:10.3322/caac.21357
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European Medicines Agency: public Summary of Opinion on Orphan Designation: obinutuzumab for the treatment of follicular lymphoma 23 July 2015. Available from: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/15/1504-public-summary-opinion-orphan-designation-obinutuzumab-treatment-follicular-lymphoma_en.pdf. Accessed January, 2020.
   Google Scholar
• Busco S, Buzzoni C; AIRTUM Working Group, et al. Italian cancer figures--Report 2015: the burden of rare cancers in Italy [published correction appears in Epidemiol Prev. 2016 Mar-Apr;40(2):83]. Epidemiol Prev. 2016;40(1 Suppl 2):1–120. doi:10.19191/EP16.1S2.P001.035.
   PubMedGoogle Scholar
• Nastoupil L, Sinha R, Hirschey A, Flowers CR. Considerations in the initial management of follicular lymphoma. Community Oncol. 2012;9(11):S53–S60. doi:10.1016/j.cmonc.2012.09.015
   Google Scholar
• AIOM. Linee guida linfomi [Lymphoma guidelines]. Edizione 2018. Available from: https://www.aiom.it/linee-guida-aiom-2018-linfomi/. Accessed April 8, 2021.
   Google Scholar
• Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2007;216–225. doi:10.1182/asheducation-2007.1.216
   Google Scholar
• Luminari S, Bellei M, Biasoli I, Federico M. Follicular lymphoma - treatment and prognostic factors. Rev Bras Hematol Hemoter. 2012;34(1):54–59. doi:10.5581/1516-8484.20120015
   PubMedGoogle Scholar
• Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265. doi:10.1182/blood-2003-12-4434
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–4562. doi:10.1200/JCO.2008.21.3991
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15(3):1110–1117. doi:10.1200/JCO.1997.15.3.1110
   PubMed Web of Science ®Google Scholar
• Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Health Technol Assess. 2012;16(37):1–iv. doi:10.3310/hta16370
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Guidelines B-Cell Lymphoma. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed April 8, 2021.
   Google Scholar
• Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v83–v90. doi:10.1093/annonc/mdw400
   PubMed Web of Science ®Google Scholar
• Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13(1):140–147. doi:10.1200/JCO.1995.13.1.140
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Gazyvaro® - Summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/gazyvaro-epar-product-information_en.pdf. Accessed April 8, 2021.
   Google Scholar
• Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393–4402. doi:10.1182/blood-2009-06-225979
   PubMed Web of Science ®Google Scholar
• Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011;118(2):358–367. doi:10.1182/blood-2010-09-305847
   PubMed Web of Science ®Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377(14):1331–1344. doi:10.1056/NEJMoa1614598
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare. J Clin Oncol. 2015;33(23):2516–2522. doi:10.1200/JCO.2014.59.7534
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Bachy E, Ghesquières H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096–1101. doi:10.1002/ajh.24492
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, Kuntz KM. ISPOR-SMDM modeling good research practices task force. modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. Value Health. 2012;15(6):796–803. doi:10.1016/j.jval.2012.06.012
   PubMed Web of Science ®Google Scholar
• Capri S, Ceci A, Terranova L, Merlo F, Mantovani L. Guidelines for Economic Evaluations in Italy: recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Inf J. 2001;35(1):189–201. doi:10.1177/009286150103500122
   Google Scholar
• Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5(5):303–313.
   PubMed Web of Science ®Google Scholar
• Launonen A, Casulo C, Pott C, Rusconi C, Hernandez J, Davies A. Clinical outcomes of patients with intermediate‐to‐high‐risk follicular lymphoma (FL) in the Gallium phase III study. Hematol Oncol. 2019;37:386–387. doi:10.1002/hon.56_2631
   Google Scholar
• Bachy E, Seymour JF, Feugier P, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37(31):2815–2824. doi:10.1200/JCO.19.01073
   PubMed Web of Science ®Google Scholar
• Scalone L, Cortesi PA, Ciampichini R, et al. Italian population-based values of EQ-5D health states. Value Health. 2013;16(5):814–822. doi:10.1016/j.jval.2013.04.008
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509–518. doi:10.1111/j.1524-4733.2010.00700.x
   PubMed Web of Science ®Google Scholar
• Szende A, Janssen B, Cabases J, eds. Self-Reported Population Health: An International Perspective Based on EQ-5D. Dordrecht (NL): Springer; 2014. doi:10.1007/978-94-007-7596-1.
   Google Scholar
• European Medicines Agency. Rituximab - Summary of product characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera. Accessed April 8, 2021.
   Google Scholar
• SORESA. SORESA anagrafica beni (28-08-2020). Available from: www.soresa.it. Accessed April 8, 2020.
   Google Scholar
• Roche Market Research. Data On-File.
   Google Scholar
• Della Salute M. Remunerazione Prestazioni Di Assistenza Ospedaliera per Acuti, Assistenza Ospedaliera Di Riabilitazione e Di Lungodegenza Post Acuzie e Di Assistenza Specialistica Ambulatoriale. Decreto 10/2012 e pubblicato in GU Serie Generale n.23 del 28-1–2013.
   Google Scholar
• Pradelli L, Bellone M. Market Access in Italy. In: Kockaya G, Wertheimer A, editors. Pharmaceutical Market Access in Deleveloped Markets. SEEd Medical Publishers Srl.
   Google Scholar
• dei Ministri PD. La conferenza permanente per i rapporti tra lo Stato, le Regioni e le Provincie Autonome di Trento e Bolzano. 189/CSR of 18/10/2018.
   Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853–2858. doi:10.1200/JCO.2009.26.5827
   PubMed Web of Science ®Google Scholar
• AIMAC. I Linfomi Non Hodgkin [Understanding Non-Hodgkin’s Lymphomas] (No. 18). La Collana del Girasole; 2015. Available from: https://www.aimac.it/libretti-tumore/linfomi-non-hodgkin. Accessed July 2019.
   Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018. doi:10.1056/NEJMoa1314583
   PubMed Web of Science ®Google Scholar
• Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188–1199. doi:10.1200/JCO.19.00010
   PubMed Web of Science ®Google Scholar
• Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer. 2010;102(1):80–86. doi:10.1038/sj.bjc.6605417
   PubMed Web of Science ®Google Scholar
• Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health. 2008;11(5):791–799. doi:10.1111/j.1524-4733.2007.00302.x
   PubMed Web of Science ®Google Scholar
• Direzione generale della programmazione sanitaria - Ufficio 6. Ministero della Salute (2018). Rapporto annuale sull’attività di ricovero ospedaliero (SDO). Available from: https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=2898. Accessed July 2020.
   Google Scholar
• Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: stato dell’arte della metodologia e applicazione di un algoritmo farmacoeconomico. [Clinical benefit and economic value: methodology and an economic application]. Pharmaco Econ. 2003;5:53–67.
   Google Scholar
• Vellopoulou K, Tzanetakos C, Theodoropoulou T, Akratos A, Maniadakis N. Cost-effectiveness analysis of obinutuzumab for the treatment of patients with previously untreated advanced follicular lymphoma in Greece. Value in Health. 2018;21:S38.
   Web of Science ®Google Scholar
• Hofmann S, Himmler S, Ostwald D, Dünzinger U, Launonen A, Thuresson PO. The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany. J Comp Eff Res. 2020;9(14):1017–1026. doi:10.2217/cer-2020-0131
   Web of Science ®Google Scholar